Physician profile
William J Lyons
NPI 1831166099
$20,266.06
in general payments reported to CMS, 2019-2025
30 companies · $2,260 in 2025
The $2,260 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,308 · 2020: $592 · 2021: $1,667 · 2022: $2,275 · 2023: $6,503 · 2024: $5,661 · 2025: $2,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,430 · Travel and Lodging: $4,993.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,430.36 |
| Travel and Lodging | $4,993.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,219.37 | 2019-2025 | Watchman Access System, Watchman Flx, Watchman |
| Abbott Laboratories | $4,045.65 | 2019-2025 | Mitraclip, Navitor, Aveir |
| Edwards Lifesciences Corporation | $3,171.48 | 2019-2025 | Pascal, Evoque |
| Medtronic, INC. | $1,571.87 | 2021-2025 | Corevalve Evolut R, Micra, Symplicity G3 |
| Esperion Therapeutics, INC. | $1,205.64 | 2020-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $1,153.90 | 2019-2025 | |
| Amgen INC. | $1,021.41 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $626.24 | 2019-2025 | Jardiance |
| Pfizer INC. | $569.51 | 2020-2025 | |
| Amarin Pharma, INC. | $556.04 | 2019-2023 | |
| Philips North America LLC | $425.41 | 2022-2025 | Mcot, (Ck7) Extended Holter |
| Astrazeneca Pharmaceuticals LP | $365.78 | 2019-2025 | Wainua, Farxiga, Lokelma |
| Janssen Pharmaceuticals, INC | $261.10 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $210.85 | 2023-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $205.48 | 2019-2025 | Eliquis, Camzyos |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $148.71 | 2023-2025 | Ffrct |
| Alnylam Pharmaceuticals INC. | $139.21 | 2025 | Amvuttra, Onpattro |
| Regeneron Healthcare Solutions, INC. | $113.55 | 2021-2022 | |
| Novo Nordisk INC | $37.60 | 2024-2025 | Ozempic, Wegovy |
| Bardy Diagnostics, INC. | $33.64 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $33.02 | 2020-2023 | Lifevest |
| Cvrx, INC. | $30.91 | 2024 | Barostim Neo System |
| Cardiva Medical, INC. | $22.36 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Kiniksa Pharmaceuticals, LTD. | $16.27 | 2023 | Arcalyst |
| Gilead Sciences, INC. | $14.40 | 2019 | |
| Lundbeck LLC | $13.89 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $13.50 | 2024 | |
| Lilly USA, LLC | $13.13 | 2023 | Mounjaro |
| W. L. Gore & Associates, INC. | $13.08 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Lyons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.